--- title: Atropine to Prevent Nausea and Vomiting After Spinal Anesthesia for Caesarean Section nct_id: NCT00921102 overall_status: COMPLETED phase: PHASE4 sponsor: University of Parma study_type: INTERVENTIONAL primary_condition: Cesarean Section countries: Italy canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00921102.md" clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00921102" ct_last_update_post_date: 2009-06-16 last_seen_at: "2026-05-12T06:24:57.814Z" source: ClinicalTrials.gov (mirrored, no enrichment) --- # Atropine to Prevent Nausea and Vomiting After Spinal Anesthesia for Caesarean Section **Official Title:** Intrathecal Atropine to Prevent Nausea and Vomiting After Spinal Anesthesia With Morphine for Elective Caesarean Section: a Randomized Controlled Trial **NCT ID:** [NCT00921102](https://clinicaltrials.gov/study/NCT00921102) ## Key Facts - **Status:** COMPLETED - **Phase:** PHASE4 - **Study Type:** INTERVENTIONAL - **Target Enrollment:** 216 - **Lead Sponsor:** University of Parma - **Conditions:** Cesarean Section, Anesthesia,Spinal, Postoperative Nausea and Vomiting - **Start Date:** 2007-05 - **Completion Date:** 2008-05 - **CT.gov Last Update:** 2009-06-16 ## Brief Summary The aim of this study is to assess the efficacy of atropine in preventing nausea and vomiting after spinal anesthesia with local anesthetic and morphine for elective Caesarean section. Patients enrolling in the study will be assigned to one of three groups. One will receive a small dose of intrathecal atropine; another will receive small-dose intravenous atropine; the third group will receive placebo. ## Detailed Description Intrathecal (IT) morphine grants effective, durable and safe analgesia after Caesarean section. The most common adverse effects after IT morphine are widespread pruritus and postoperative nausea and vomiting (PONV). Postoperative nausea and vomiting is multifactorial in origin; in addition to general and pre-existing risk factors, such as elevated gonadotropin and progesterone serum levels, parturients undergoing Caesarean section are exposed to drug-induced, hemodynamic and surgical (manipulation of the uterus) stimuli. Anticholinergic agents, and particularly scopolamine, have long been known to decrease opioid-related nausea and vomiting, although their narrow therapeutic range and inconvenient route of administration (typically transdermal) has limited their application. Anticholinergic agents are thought to act via inhibition of muscarinic receptors in several regions of the medulla oblongata, which are implicated with nausea and vomiting generation; in addition to the chemoceptor trigger zone, these receptors are particularly concentrated in, but not limited to the nucleus tractus solitarius. Cholinergic receptors have been typically associated with motion sickness, but cholinergic agonists such as neostigmine have been shown to increase the incidence of PONV, especially when injected intrathecally. Anticholinergic agents with muscarinic selectivity may be effective in preventing and treating PONV. Intravenous (IV) administration of scopolamine or atropine, but not glycopyrrolate, reduces the incidence of PONV. Intuitively, as glycopyrrolate does not cross the blood-brain barrier, most postoperative anti-emetic effects of anticholinergic drugs should be mediated by central receptors. Few studies have specifically evaluated the antiemetic effect of IV atropine after balanced general or opioid-based regional anesthesia, with conflicting results. Atropine may represent a valid alternative to scopolamine and its adverse effects; however, its apparent duration of action is "brief" (minutes to 1 hour) when administered IV. After we became aware of several observations by Ramaioli and De Amici on the efficacy of small-dose intrathecal (IT) atropine for the treatment of PONV after IT morphine administration, we set out to investigate the use of this agent for prophylaxis of PONV in a high-risk population, such as patients receiving IT morphine for postoperative analgesia after elective Caesarean section. ## Eligibility - **Minimum age:** 18 Years - **Sex:** FEMALE - **Healthy Volunteers:** No ``` Inclusion Criteria: * Patients scheduled for elective Cesarean section at up to 42 weeks and 2 days * Patients in ASA Physical Status Class I or II * Informed written consent to participation * No known gestosis Exclusion Criteria: * Any known fetal pathology * Indication to general anesthesia * Known allergy to any of the study drugs * Baseline bradycardia or any cardiovascular disease ``` ## Arms - **Control** (PLACEBO_COMPARATOR) — Patients in this group will receive both an intrathecal and intravenous injection of saline solution, as a placebo comparator. - **Intrathecal Atropine** (EXPERIMENTAL) — Patients in this group will receive intrathecal atropine as a prophylactic antiemetic agent. They will also receive intravenous saline solution to maintain blinding. - **IV Atropine** (ACTIVE_COMPARATOR) — Patients in this group will receive a small dose of atropine via the intravenous route to examine its possible antiemetic activity. They will also receive intravenous saline solution to maintain blinding. ## Interventions - **Bupivacaine** (DRUG) — 12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally - **Morphine** (DRUG) — 200 µg of a 200 µg/ml solution, intrathecally - **Isotonic saline solution** (DRUG) — 0.9% NaCl solution 0.1 ml, intrathecally in group Control and IV Atropine 0.1 ml, intravenously in group Control and Intrathecal Atropine - **Atropine** (DRUG) — 100 µg of a 1 mg/ml preservative-free solution * intrathecally in group Intrathecal Atropine * intravenously in group IV Atropine ## Primary Outcomes - **Incidence of postoperative nausea and vomiting (PONV) as expressed by at least one rating > 3 on a numerical rating scale (0-10).** _(time frame: 12 hours post-operatively)_ ## Secondary Outcomes - **Incidence and prevalence of PONV up to 24 h postoperatively, expressed as both ratings on a numerical rating scale and as the area under the curve of these ratings over time.** _(time frame: Up to 24 h postoperatively)_ - **Incidence of atropine-related side effects such as xerostomia, anxiety, tachycardia.** _(time frame: Up to 24 h postoperatively)_ - **Postoperative pain expressed as time to first request for supplemental analgesia and as rating on a numerical rating scale.** _(time frame: Up to 24 h postoperatively)_ ## Locations (2) - University of Messina, Messina, ME, Italy - University and Hospital of Parma (Azienda Ospedaliero-Universitaria di Parma), Parma, PR, Italy ## Recent Field Changes (last 30 days) - `status.overallStatus` — added _(2026-05-12)_ - `status.primaryCompletionDate` — added _(2026-05-12)_ - `status.completionDate` — added _(2026-05-12)_ - `status.lastUpdatePostDate` — added _(2026-05-12)_ - `design.phases` — added _(2026-05-12)_ - `design.enrollmentCount` — added _(2026-05-12)_ - `eligibility.criteria` — added _(2026-05-12)_ - `eligibility.minAge` — added _(2026-05-12)_ - `eligibility.sex` — added _(2026-05-12)_ - `outcomes.primary` — added _(2026-05-12)_ - `outcomes.secondary` — added _(2026-05-12)_ - `armsInterventions.arms` — added _(2026-05-12)_ - `armsInterventions.interventions` — added _(2026-05-12)_ - `sponsor.lead` — added _(2026-05-12)_ - `results.hasResults` — added _(2026-05-12)_ - `locations.university of messina|messina|me|italy` — added _(2026-05-12)_ - `locations.university and hospital of parma (azienda ospedaliero-universitaria di parma)|parma|pr|italy` — added _(2026-05-12)_ --- *Canonical: https://parkinsonspathways.com/agent/trials/NCT00921102.md* *Source data (authoritative): https://clinicaltrials.gov/study/NCT00921102* *This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*